Loading viewer...
investor_presentation
Format: PDF investor_presentation
November 2018 Nasdaq : MESO ASX: MSBOperational Highlights and Financial Results for the Quarter Ended September 30, 2018
Nasdaq : MESO ASX: MSBOperational Highlights and
Financial Results for the
Quarter Ended September 30, 2018CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This presentation includes forward-looking statements thatrelate tofuture events orourfuture financial performance andinvolve known andunknown risks, uncertainties andother factors thatmay cause ouractual results,
levels ofactivity, performance orachievements todiffer materially from anyfuture results, levels ofactivity, performance orachievements expressed orimplied bythese forward-looking statements .Wemake such forward -
looking statements pursuant tothesafe harbor provisions ofthePrivate Securities Litigation Reform Actof1995 andother federal securities laws.Allstatements other than statements ofhistorical facts contained inthis
presentation areforward-looking statements .Words such as,butnotlimited to,“believe, ”“expect, ”“anticipate, ”“estimate, ”“intend, ”“plan, ”“targets, ”“likely, ”“will,”“would, ”“could, ”andsimilar expressions orphrases identify
forward -looking statements .Wehave based these forward -looking statements largely onourcurrent expectations andfuture events ,recent changes inregulatory laws, andfinancial trends thatwebelieve may affect our
financial condition, results ofoperation, business strategy andfinancial needs .These statements may relate to,butarenotlimited to:expectations regarding thesafety orefficacy of,orpotential applications for,Mesoblast's
adult stem celltechnologies ;expectations regarding thestrength ofMesoblast's intellectual property, thetimeline forMesoblast's regulatory approval process, andthescalability andefficiency ofmanufacturing processes ;
expectations about Mesoblast's ability togrow itsbusiness andstatements regarding itsrelationships with current andpotential future business partners andfuture benefits ofthose relationships ;statements concerning
Mesoblast's share price orpotential market capitalization; andstatements concerning Mesoblast's capital requirements andability toraise future capital, among others .Forward-looking statements should notberead asa
guarantee offuture performance orresults, andactual results may differ from theresults anticipated inthese forward-looking statements, andthedifferences may bematerial andadverse. You should read thispresentation
together with ourfinancial statements andthenotes related thereto, aswellastheriskfactors, inourmost recently filed reports with theSEC oronourwebsite .Uncertainties andrisks thatmay cause Mesoblast's actual
results, performance orachievements tobematerially different from those which may beexpressed orimplied bysuch statements, include, without limitation :risks inherent inthedevelopment andcommercialization of
potential products ;uncertainty ofclinical trialresults orregulatory approvals orclearances ;government regulation ;theneed forfuture capital ;dependence upon collaborators ;andprotection ofourintellectual property rights,
Preview truncated — download the full document for the complete content.
presentation
investor_presentation
24 Pages
Epiroc
investor_presentation
LianBio
investor_presentation
Ternium